These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 7904983)

  • 1. The effect of cimetidine on the pharmacokinetics of single oral doses of alfuzosin.
    Desager JP; Harvengt C; Bianchetti G; Rosenzweig P
    Int J Clin Pharmacol Ther Toxicol; 1993 Nov; 31(11):568-71. PubMed ID: 7904983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of alfuzosin after single oral administration to healthy volunteers, of three different doses.
    Salva P; Bianchetti G; Morselli P; Garcia-Teresa G; Costa J
    Biopharm Drug Dispos; 1992 Nov; 13(8):583-90. PubMed ID: 1358243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia.
    Guay DR
    Am J Geriatr Pharmacother; 2004 Mar; 2(1):14-23. PubMed ID: 15555475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin.
    Mück W; Ritter W; Dietrich H; Frey R; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):261-4. PubMed ID: 9208343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alfuzosin: a clinically uroselective alpha1-blocker.
    Höfner K; Jonas U
    World J Urol; 2002 Apr; 19(6):405-12. PubMed ID: 12022709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of cimetidine on the pharmacodynamics, pharmacokinetics and biotransformation of a single oral dose of alpidem.
    Desager JP; Hulhoven R; Harvengt C; Bianchetti G
    Int J Clin Pharmacol Ther Toxicol; 1990 Dec; 28(12):498-503. PubMed ID: 1982281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL).
    Michel MC; Chapple CR
    Eur Urol; 2006 Mar; 49(3):501-8; discussion 508-9. PubMed ID: 16442211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
    Nordling J
    BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia.
    Kuritzky L; Rosenberg MT; Sadovsky R
    Int J Clin Pract; 2006 Mar; 60(3):351-8. PubMed ID: 16494652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of interaction between zolpidem and H2 antagonists, cimetidine and ranitidine.
    Hulhoven R; Desager JP; Harvengt C; Hermann P; Guillet P; Thiercelin JF
    Int J Clin Pharmacol Res; 1988; 8(6):471-6. PubMed ID: 3253224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily.
    Hartung R; Matzkin H; Alcaraz A; Emberton M; Harving N; van Moorselaar J; Elhilali M; Vallancien G;
    J Urol; 2006 Feb; 175(2):624-8; discussion 628. PubMed ID: 16407011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
    Martorana G; Giberti C; Di Silverio F; von Heland M; Rigatti P; Colombo R; Casadei G; Pacifico P
    Eur Urol; 1997; 32(1):47-53. PubMed ID: 9266231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia.
    Rosen R; Seftel A; Roehrborn CG
    Int J Impot Res; 2007; 19(5):480-5. PubMed ID: 17717526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of repeat dosing with cimetidine on the pharmacokinetics of intravenous granisetron in healthy volunteers.
    Youlten L
    J Pharm Pharmacol; 2004 Feb; 56(2):169-75. PubMed ID: 15005875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alfuzosin (10 mg) does not affect blood pressure in young healthy men.
    Mondaini N; Giubilei G; Ungar A; Gontero P; Cai T; Gavazzi A; Bartoletti R; Geppetti P; Carini M
    Eur Urol; 2006 Dec; 50(6):1292-6; discussion 1297-8. PubMed ID: 16837126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered pharmacokinetics of oral flecainide by cimetidine.
    Tjandra-Maga TB; van Hecken A; van Melle P; Verbesselt R; de Schepper PJ
    Br J Clin Pharmacol; 1986 Jul; 22(1):108-10. PubMed ID: 3741720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
    Resnick MI; Roehrborn CG
    Prostate Cancer Prostatic Dis; 2007; 10(2):155-9. PubMed ID: 17211442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration.
    Mottet N; Bressolle F; Delmas V; Robert M; Costa P
    Eur Urol; 2003 Jul; 44(1):101-5. PubMed ID: 12814682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of dose increase or cimetidine co-administration on albendazole bioavailability.
    Schipper HG; Koopmans RP; Nagy J; Butter JJ; Kager PA; Van Boxtel CJ
    Am J Trop Med Hyg; 2000; 63(5-6):270-3. PubMed ID: 11421376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of theophylline and the H2-antagonist drugs cimetidine and ranitidine.
    Dal Negro R; Pomari C; Zoccatelli O; Trevisan F; Carloni C; Turco P
    Int J Clin Pharmacol Ther Toxicol; 1984 Apr; 22(4):221-6. PubMed ID: 6325354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.